$0.42
-0.02 (-4.78%)
Open$0.44
Previous Close$0.44
Day High$0.44
Day Low$0.41
52W High$1.51
52W Low$0.33
Volume—
Avg Volume672.5K
Market Cap4.73M
P/E Ratio—
EPS$-1.90
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+6,504.0% upside
Current
$0.42
$0.42
Target
$27.73
$27.73
$20.43
$27.73 avg
$35.07
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.57M | 1.60M | 1.25M |
| Net Income | 4.2K | 5.8K | 3.4K |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| EBITDA | 8.2K | 8.5K | 6.5K |
| Free Cash Flow | 4.7K | 4.2K | 2.8K |
| Rev Growth | -8.5% | +15.0% | -6.0% |
| Debt/Equity | 0.92 | 0.88 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |